Results 271 to 280 of about 450,783 (333)

Angiotensin Receptors and Their Antagonists

New England Journal of Medicine, 1996
Angiotensins are peptide hormones derived from the protein precursor angiotensinogen by the sequential actions of proteolytic enzymes (Figure 1). The classic pathway of angiotensin synthesis includes a reaction catalyzed by angiotensin-converting enzyme (ACE), which occurs not only in plasma but also in the kidneys, brain, adrenal glands, ovaries, and ...
T L, Goodfriend, M E, Elliott, K J, Catt
openaire   +2 more sources

Nonpeptide Angiotensin II Receptor Antagonists

American Journal of Hypertension, 1990
Although the most direct way to interfere with the renin-angiotensin system (RAS) is at the level of the angiotensin II (AII) receptor, the currently available AII receptor antagonists are peptides still retaining significant agonistic properties with the obvious drawbacks of limited stability and lack of oral activity.
Pieter B M W M Timmermans, David J Carini, Andrew T Chiu   +2 more
exaly   +3 more sources

Angiotensin II receptor antagonists and receptor subtypes

Trends in Endocrinology & Metabolism, 1992
Recently discovered nonpeptide angiotensin II receptor antagonists represent a new class of potential drugs for the treatment of hypertension and congestive heart failure. Further, these antagonists have been successfully used as selective research tools for physiologic studies of angiotensin H and defining angiotensin II receptor subtypes.
P C, Wong, A T, Chiu, J V, Duncia, W F, Herblin, R D, Smith, P B, Timmermans   +5 more
openaire   +2 more sources

Comparison of angiotensin II receptor antagonists [PDF]

European Journal of Clinical Investigation, 2001
Nonpeptide orally active angiotensin II type 1 (AT1) receptor antagonists are the most specific means presently available to block the renin‐angiotensin enzymatic cascade. Six of these drugs have already been licensed in Europe and in the United States for the treatment of high blood pressure, and additional candidates are in the pipeline.
W, Kirch, B, Horn, J, Schweizer
exaly   +3 more sources

Selective blockade of angiotensin responses in the rabbit isolated vas deferens by angiotensin receptor antagonists.

Journal of Pharmacology and Experimental Therapeutics, 1990
We examined the effect of two angiotensin receptor antagonists on neuromodulatory and prostaglandin-producing effects of angiotensin II in the rabbit isolated vas deferens because prior studies have established that angiotensins selectively influence the
G. Trachte, C. Ferrario, M. Khosla
semanticscholar   +1 more source

Nonpeptide angiotensin II receptor antagonists.

Trends in Pharmacological Sciences, 1991
Substantial progress has been made recently in the development of nonpeptide angiotensin II receptor antagonists, a goal that has long remained an unmet challenge. Pieter Timmermans and colleagues review the pharmacology and the course of events that led to the identification of the lead compound and clinical candidate DuP753. Nonpeptide angiotensin II
P. B. Timmermans, Pancras C. Wong, A. T. Chiu, W. Herblin   +3 more
semanticscholar   +3 more sources

Angiotensin II receptor antagonists and the kidney

Current Opinion in Nephrology and Hypertension, 1994
The kidney is not only the source of circulating renin, which determines the plasma concentration of angiotensin II, but it is also one of the main targets of angiotensin II. Thus, angiotensin II exerts an important physiologic influence on renal function through its ability to modulate renal hemodynamics as well as glomerular and tubular functions ...
Burnier M, Brunner HR
openaire   +3 more sources

Overview of angiotensin II-receptor antagonists

The American Journal of Cardiology, 1998
T renin–angiotensin system is integral to the mechanisms that regulate cardiovascular homeostasis. The renin–angiotensin system has an important role in the pathophysiology of hypertension and heart failure via the vasoconstricting effects of angiotensin II, which sustain elevated blood pressure levels in hypertension and increase afterload in chronic ...
B, Pitt, M A, Konstam
openaire   +2 more sources

Dihydropyrimidine angiotensin II receptor antagonists

Journal of Medicinal Chemistry, 1992
The discovery of the nonpeptide angiotensin II (AII) receptor antagonist losartan, previously called DuP 753, has stimulated considerable interest in the synthesis of novel analogs of this compound. Our efforts in this area have resulted in the discovery of dihydropyrimidines as potent AII receptor antagonists. The chemistry leading to this novel class
K S, Atwal, S Z, Ahmed, J E, Bird, C L, Delaney, K E, Dickinson, F N, Ferrara, A, Hedberg, A V, Miller, S, Moreland, B C, O'Reilly   +9 more
openaire   +2 more sources

Angiotensin Receptor Antagonists and Cardiovascular Remodeling

1998
Angiotensin (Ang) II is one of the key hormones involved in cardiovascular homeostasis. It has potent vasoconstrictor effects and is directly involved in the vascular and cardiac remodeling observed in response to chronic or acute hypertension. Two major Ang II receptor subtypes, AT1 and AT2, have been described, and their roles in vivo and in vitro ...
Sabri, K., Chassagne, Catherine, Lévy, B., Samuel, J.L., Rappaport, L.   +4 more
openaire   +1 more source